

TranXenoGen

[View the current TranXenoGen Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/10327-TranXenoGen.html)

(<http://www.bioportfolio.com/biocorporate/10327-TranXenoGen.html>)

Contact Details:

**800 BOSTON TURNPIKE
SHREWSBURY
MA
01545
United States of America**

Tel: 508 936 4200

Fax:

Email:

TranXenoGen is developing transgenic technologies for the production of transgenic animals, including a non-viral method for the transfection of large transgenes into chicken eggs (Direct-Egg Transfection). The goal is transgenic chickens that express the recombinant protein in the albumin fraction of their eggs.

TranXenoGen is also developing a technology (Gene-Testes Transfection), designed to be applicable in many species of animals. The technology targets transfection of a transgene into the male animal in such a way that the male animal will produce transgenic sperm. Consequently, the male can be easily bred to generate transgenic animals.

TranXenoGen's R&D projects also include:

Utilizing avian stem cells to improve the flexibility and effectiveness of the transgenic chicken platform.

Developing of an in-licensed novel human protein, anti-neoplastic urinary protein, "ANUP", from Antitumor Research Products. ANUP is believed to be an anti-cancer protein, which is effective in treating cervical and other cancers. TranXenoGen is currently in early stage development and in-vitro testing of the product. If successful, future development in animal models and preclinical testing will commence.

Recent Publications by TranXenoGen:



- [A potential antitumor peptide therapeutic derived from antineoplastic urinary protein.](#)
New therapies in cancer treatment are focusing on multifaceted approaches... 19th February, 2005
TranXenoGen Inc., Technology Development, 800 Boston Turnpike, Shrewsbury, - Peptides. 2004
Apr;25(4):543-9. ([DOI Direct Link](#))

TranXenoGen Patents:



- 7326679- [Anticancer peptide compositions](#)
- 6753457- [Nuclear reprogramming using cytoplasmic extract](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

